Biogen ends agreement with Acorda for multiple sclerosis drug Fampyra

Bio­gen is hand­ing back ex-US com­mer­cial­iza­tion rights to Acor­da Ther­a­peu­tics for the mul­ti­ple scle­ro­sis drug Fampyra.

Acor­da will have the drug in-house ef­fec­tive Jan. 1, 2025, now that Bio­gen has de­cid­ed to ter­mi­nate the li­cense and col­lab­o­ra­tion agree­ment be­tween the two com­pa­nies. The drug is mar­ket­ed as Fampyra (fam­pri­dine) in the EU as a treat­ment to im­prove the walk­ing of adults with mul­ti­ple scle­ro­sis and a walk­ing dis­abil­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.